Edwards Lifesciences (EW)Officer sold ~$127K

~$127K

Approx. value · 1,500 sh @ $84.60

44K

Holds after · shares reported

Traded

May 22, 2026

Filed

May 22, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
2. Mar 27, 2026FDARecall: Edwards EVOQUE tricuspid delivery system REF:9850TDS Sterile EO
3. Mar 27, 2026CongressDisclosed purchase of EW — reported range $1,001 - $15,000
4. Apr 2, 2026Insider · 1 personInsiders: 2 sales (~$1.8M)
5. Apr 6, 2026InsiderOfficer sold ~$83K of EW shares in the open market
6. Apr 9, 2026Insider · 1 personInsiders: 2 sales (~$1.0M)
7. Apr 17, 2026FDAFDA device clearance: Edwards eSheath+ introducer set
8. Apr 23, 2026Company filing · Form 8-K · ResultsReported its results
9. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
10. May 1, 2026Insider · 1 personInsiders: 2 sales (~$85K)
11. May 2, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.”
12. May 4, 2026InsiderOfficer sold ~$86K of EW shares in the open market
13. May 7, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“of Certain Officers Approval of the Amended and Restated Long-Term Stock Incentive Compensation Program At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term Stock Incentive Compensation Program (the “Long-Term Stock Program”).”
14. May 11, 2026InsiderOfficer sold ~$47K of EW shares in the open market
15. May 12, 2026Insider · 1 personInsiders: 2 sales (~$2.8M)
16. May 15, 2026Insider · 1 personInsiders: 2 sales (~$1.5M)
17. May 18, 2026InsiderOfficer sold ~$50K of EW shares in the open market
18. May 22, 2026 · this disclosureInsiderOfficer sold ~$127K of EW shares in the open market

What came next

1. May 27, 2026InsiderOfficer sold ~$2M of EW shares in the open market
2. May 29, 2026InsiderOfficer sold ~$49K of EW shares in the open market
3. Jun 5, 2026FDAFDA device clearance: Fogarty Spring Clips, Handleless Clamps, and Clamp Inserts
4. Jun 11, 2026FDAFDA device clearance: Respiration Rate algorithm
5. Jun 17, 2026InsiderCEO sold ~$46K of EW shares in the open market
6. Jun 26, 2026FDAFDA device clearance: ECLIPTIS Left Atrial Appendage Exclusion System (ECS135); ECLIPTIS Left Atrial Appendage Exclusion System (ECS140); ECLIPTIS Left Atrial Appendage Exclusion Sy…
7. Jun 30, 2026InsiderOfficer sold ~$57K of EW shares in the open market
8. Jul 10, 2026InsiderOfficer sold ~$57K of EW shares in the open market
9. Jul 23, 2026Company filing · Form 8-K · ResultsReported its results
10. Jul 23, 2026Government · Federal Register noticeUnited States v. Edwards LifeSciences Corp. and Genesis MedTech Group Limited; Proposed Final Judgment and Competitive Impact Statement
11. Jul 27, 2026InsiderCEO sold ~$245K of EW shares in the open market
12. Jul 28, 2026InsiderOfficer sold ~$819K of EW shares in the open market
13. Jul 30, 2026InsiderOfficer sold ~$13K of EW shares in the open market
14. Aug 11, 2026InsiderOfficer sold ~$57K of EW shares in the open market
15. Aug 25, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027.”
16. Aug 26, 2026Insider · 2 peopleInsiders: 3 sales (~$3.0M)
17. Aug 28, 2026InsiderOfficer sold ~$238K of EW shares in the open market
18. Aug 31, 2026InsiderOfficer sold ~$50K of EW shares in the open market
19. Sep 11, 2026InsiderOfficer sold ~$54K of EW shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Edwards Lifesciences

For Edwards Lifesciences, OQRO holds 11 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 21 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EW page.

Other recent filings by Daveen Chopra, CVP, TMTT & Surgical

• SEC Form 4 at Edwards Lifesciences (EW)Aug 26, 2026
• SEC Form 4 at Edwards Lifesciences (EW)Aug 26, 2026
• SEC Form 4 at Edwards Lifesciences (EW)Dec 11, 2025
• SEC Form 4 at Edwards Lifesciences (EW)Aug 25, 2025
• SEC Form 4 at Edwards Lifesciences (EW)May 22, 2025

The full history of Daveen Chopra, CVP, TMTT & Surgical is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Edwards Lifesciences

• SEC Form 4Oct 8, 2026
• SEC Form 4Sep 11, 2026
• SEC Form 4Aug 31, 2026
• SEC Form 4Aug 28, 2026
• SEC Form 4Aug 26, 2026
• SEC Form 4Aug 26, 2026

Everything OQRO holds on this company is on its EW page.